ADA compliant RF shielded door systems and related methods von CARDUCCI DOMINICK, MCNEMAR GLENN A, CASTLE MARY R, WIATR ROBERT A

Volltext bestellen

ADA COMPLIANT RF SHIELDED DOOR SYSTEMS AND RELATED METHODS von CARDUCCI DOMINICK, MCNEMAR GLENN A, CASTLE MARY R, WIATR ROBERT A

Volltext bestellen

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) von Pili, Roberto, Quinn, David I, Hammers, Hans J, Monk, Paul, George, Saby, Dorff, Tanya B, Olencki, Thomas, Shen, Li, Orillion, Ashley, Lamonica, Dominick, Fragomeni, Roberto S, Szabo, Zsolt, Hutson, Alan, Groman, Adrienne, Perkins, Susan M, Piekarz, Richard, Carducci, Michael A

Volltext

Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870) von Pili, Roberto, Quinn, David I., Hammers, Hans J., Monk, Paul, George, Saby, Dorff, Tanya B., Olencki, Thomas, Shen, Li, Orillion, Ashley, Lamonica, Dominick, Fragomeni, Roberto S., Szabo, Zsolt, Hutson, Alan, Groman, Adrienne, Perkins, Susan M., Piekarz, Richard, Carducci, Michael A.

Volltext

Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870) von Pili, Roberto, Quinn, David I., Hammers, Hans J., Monk, J. Paul, George, Saby, Dorff, Tanya B., Olencki, Thomas, Shen, Li, Lamonica, Dominick, Hutson, Alan, Groman, Adrienne, Perkins, Susan M., Piekarz, Richard, Carducci, Michael

Volltext

Abstract CT015: Results from a phase III study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP7870) von Pili, Roberto, Quinn, David I, Hammers, Hans J, Monk, JPaul, George, Saby, Dorff, Tanya B, Olencki, Thomas, Shen, Li, Lamonica, Dominick, Hutson, Alan, Groman, Adrienne, Perkins, Susan M, Piekarz, Richard, Carducci, Michael

Volltext

Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870) von Pili, Roberto, Quinn, David I., Hammers, Hans J., Monk, Paul, George, Saby, Dorff, Tanya B., Olencki, Thomas, Shen, Li, Lamonica, Dominick M, Hutson, Alan, Groman, Adrienne, Piekarz, Richard, Carducci, Michael Anthony

Volltext